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Objectives This study sought to determine hospital variation in the use of positive inotropic agents in patients with heart
failure.
Background Clinical guidelines recommend targeted use of positive inotropic agents in highly selected patients, but data are
limited and the recommendations are not specific.
Methods We analyzed data from 376 hospitals including 189,948 hospitalizations for heart failure from 2009 through
2010. We used hierarchical logistic regression models to estimate hospital-level risk-standardized rates of ino-
trope use and risk-standardized in-hospital mortality rates.
Results The risk-standardized rates of inotrope use ranged across hospitals from 0.9% to 44.6% (median: 6.3%, inter-
quartile range: 4.3% to 9.2%). We identified various hospital patterns based on the type of agents: dobutamine-
predominant (29% of hospitals), dopamine-predominant (25%), milrinone-predominant (1%), mixed dobutamine
and dopamine pattern (32%), and mixed pattern including all 3 agents (13%). When studying the factors associ-
ated with interhospital variation, the best model performance was with the hierarchical generalized linear mod-
els that adjusted for patient case mix and an individual hospital effect (receiver operating characteristic curves
from 0.77 to 0.88). The intraclass correlation coefficients of the hierarchical generalized linear models (0.113
for any inotrope) indicated that a noteworthy proportion of the observed variation was related to an individual
institutional effect. Hospital rates or patterns of use were not associated with differences in length of stay or
risk-standardized mortality rates.
Conclusions We found marked differences in the use of inotropic agents for heart failure patients among a diverse group of hospi-
tals. This variability, occurring in the context of little clinical evidence, indicates an urgent need to define the appropri-
ate use of these medications. (J Am Coll Cardiol 2012;60:1402–9) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.011Heart failure is a leading cause of hospital admission, account-
ing for almost 1 million hospitalizations in the United States
annually (1). In the absence of major advances in the treatment
of this condition, early mortality has declined only modestly
over the past 2 decades (2). Outcome measures have revealed
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October 9, 2012:1402–9 Inotrope Use in Heart Failure Patientsmine and dobutamine have been available for decades and
were approved by the Food and Drug Administration before
the mandate to evaluate the benefits and risks of new drugs
in large trials. A third positive inotropic agent, milrinone,
was approved in 1988 for the treatment of acute decompen-
sated heart failure based on its hemodynamic effects, rather
than on clinical endpoints. Data on the comparative effective-
ness of these agents on the outcomes of patients with heart
failure are lacking (5). The only large clinical trial of milrinone
compared its effect with placebo in hospitalized patients
without end-organ hypoperfusion and found an increased
risk of adverse events (6). Other positive inotropic agents
that were tested in trials, such as amrinone and vesnarinone,
were shown to increase mortality (7,8).
The most recent guidelines for the diagnosis and man-
agement of heart failure from the American College of
Cardiology/American Heart Association recommend lim-
ited use of these agents, stating that “intravenous inotropic
drugs such as dopamine, dobutamine or milrinone might be
reasonable for those patients presenting with documented
severe systolic dysfunction, low blood pressure and evidence
of low cardiac output, with or without congestion, to
maintain systemic perfusion and preserve end-organ perfor-
mance” (9). The guidelines explicitly state that intravenous
positive inotropic agents are not recommended for hospi-
talized patients with heart failure who do not have evidence
of decreased organ perfusion. The clinical practice guide-
lines of the Heart Failure Society of America (10) and the
European Society of Cardiology (11) mirror the American
College of Cardiology/American Heart Association recom-
mendation. The recommendations are based on expert
opinion.
Little information is available about how use of positive
inotropic agents varies among hospitals. Scarce evidence and
relatively weak guideline recommendations indicate the poten-
tial for marked variation. Accordingly, we investigated treat-
ment patterns of inotrope use among patients hospitalized for
heart failure in a large network of hospitals in the United
States. We also report the relationship between inotrope use
and in-hospital RSMR and length of stay, including compar-
isons of hospitals with high and low use patterns.
Methods
Data source. We conducted a cross-sectional study using
data from Perspective, a voluntary, fee-supported database
developed by Premier, Inc. (Charlotte, North Carolina), for
measuring quality and healthcare use. As of 2010, Perspec-
tive contained data from more than 500 hospitals in the
United States, including more than 130 million cumulative
hospital discharges. Inpatient discharges represent approx-
imately 20% of all acute care inpatient hospitalizations
nationwide. In addition to the information available in the
standard hospital discharge file, Perspective contains a
date-stamped log of all billed items at the patient level,
including medications and laboratory, diagnostic, and ther-apeutic services. For this study,
patient data were deidentified in
accordance with the Health In-
surance Portability and Account-
ability Act, and hospitals were
identified by a random identifier
assigned by Premier. The Yale
University Human Investigation
Committee reviewed the proto-
col for this study and determined
that it is not considered to be
Human Subjects Research as de-
fined by the Office of Human
Research Protections.
Patients and hospitals. Our analysis included the first
episode of hospitalization per patient between January 1,
2009, and December 31, 2010, that had a principal diagnosis
of heart failure (International Classification of Diseases, Ninth
Revision, Clinical Modification codes 402.01, 402.11, 402.91,
404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1,
428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32,
428.33, 428.40, 428.41, 428.42, 428.43, and 428.9) or a
principal diagnosis of respiratory failure (International Clas-
sification of Diseases- Ninth Revision, Clinical Modifica-
tion code 518.81) combined with a secondary diagnosis of
congestive heart failure (428.0). We excluded patients
younger than 18 years or those whose physicians were
pediatricians, because our focus was not on congenital
disease. We excluded hospitalizations with a duration of 1
day, as well as transfers to or from another acute care facility
because we could not accurately assess treatment with
inotropic therapy during an entire hospitalization.
In addition to patient age, sex, race or ethnicity, and
insurance status, we used software (version 3.4, 3.5, and 3.6
for federal fiscal years 2009, 2010, and 2011, respectively)
provided by the Healthcare Costs and Utilization Project of
the Agency for Healthcare Research and Quality to classify
comorbidities from the standard hospital discharge file
based on methods described by Elixhauser and Steiner (12).
This tool provides a Diagnosis Related Group screen of
International Classification of Diseases-Ninth Revision-
Clinical Modification secondary diagnoses.
For each hospital, Perspective contains information, col-
lected from the American Hospital Association database, on
bed count, teaching status, geographic location (by census
division), and whether it serves an urban or rural population.
Participating hospitals were geographically diverse, with a
composition similar to that of acute care hospitals nation-
wide. They were predominantly small to midsized non-
teaching facilities that serve a largely urban population.
Hospital use and clinical outcomes. We assessed the use
of dopamine, dobutamine, and milrinone, which are the 3
positive inotropic agents that were noted in the American
College of Cardiology/American Heart Association Heart
Failure Guidelines. We also evaluated the hospitals’ use of a
Abbreviations
and Acronyms
CI  confidence interval
HGLM  hierarchical
generalized linear model
IQR  interquartile range
OR  odds ratio
ROC  receiver operating
characteristic
RSMR  risk-standardized
mortality ratenumber of diagnostic or therapeutic procedures, including
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heart transplantation, mechanical ventilation, and implant-
able cardioverter defibrillator, with and without cardiac
resynchronization therapy. We also assessed median length
of stay per hospital and in-hospital RSMR.
Statistical analysis. We constructed summary statistics
using frequencies and proportions for categorical data and
means, and medians and interquartile ranges (IQR) for
continuous variables.
To determine the patient and hospital characteristics that
were associated with the use of inotropic agents, we con-
structed 4 logistic regression models: 1 for overall inotropic
use and 1 for each of the 3 inotropic agents. Patient
characteristics including age group, sex, and comorbidities
were considered as candidate covariates. We selected the
variables for the final model using a stepwise algorithm.
After controlling for selected patient characteristics, we fit
logistic regression models to evaluate further the effects of
hospital characteristics (hospital size, heart failure volume,
urban or rural setting, geographic location by census divi-
sion, and teaching status). We report odds ratios (ORs) and
corresponding 95% confidence intervals (CIs) for each
significant factor.
We used hierarchical generalized linear models (HGLM)
to calculate risk-standardized use rates for use of any
inotropic agent and for use of each inotropic agent (4,13).
We selected patient characteristics used as covariates for risk
adjustment by stepwise algorithm using logistic regression
models. We performed additional scaling to ensure that the
unadjusted and adjusted rates were comparable such that the
slopes of the weighted linear regression of the unadjusted
rate and the adjusted rate were equal to 1. We also used
hierarchical logistic regression to estimate the in-hospital
RSMR, adjusting for patient characteristics including age,
gender, and all comorbidities as well as a hospital individual
effect as a random effect. We used a modified version of a
previously published 30-day mortality model with data
elements restricted to those available during the index
admission (4). We used weighted linear regression models
to assess the relationship between hospital inotrope use and
RSMR.
To assess further the contribution of institutional effect to
the variation in use of positive inotropic agents, we com-
pared the receiver operating characteristic (ROC) curves of
the logistic regression models that adjust for only patient
case mix with the ROC curves of the HGLM models that
also take into account institutional factors. We calculated
the intraclass correlation coefficient for the HGLM models
as described elsewhere (14).
Next, we categorized hospitals as either a predominant
user for 1 of the 3 agents or as a mixed user based on their
pattern of inotrope use. For these classifications, we in-
cluded only hospitals with at least 15 hospitalizations over 2
years with the use of any positive inotropic agent. We
calculated the total use by adding the number of hospital-
izations using dobutamine, dopamine, or milrinone. Be-cause patients can receive more than 1 agent during a single
hospitalization, the total use may exceed the number of
hospitalizations. We then calculated the percentage of
hospitalizations receiving each inotropic agent by hospital,
with the total use as the denominator. If a hospital had at
least 55% of hospitalizations receiving any single agent (55%
for dobutamine and dopamine, 50% for milrinone), it was
deemed a predominant user for this agent. The cutoffs were
chosen empirically based on hospital distribution of percent
use. If none of the agents exceeded 55% of total use and total
dobutamine and dopamine use was 80% or more, the hospital
was categorized as a dobutamine and dopamine mixed user.
The rest of the hospitals were characterized as dobutamine,
dopamine, and milrinone mixed users. We used Kruskal-
Wallis and chi-square tests to assess the association between
use pattern and different hospital characteristics.
We conducted analyses with SAS software version 9.2
(SAS Institute, Inc., Cary, North Carolina), estimated the
hierarchical logistic models using the GLIMMIX macro in
SAS, and created the figures with R (version 2.11.1) (15).
Results
Hospital and patient characteristics. We identified
189,948 hospitalizations from 376 hospitals that met our
enrollment criteria. Of these hospitals, 53% had more than
250 beds, 73% were nonteaching, and 78% were located in
urban settings. The median volume of patients with heart
failure per hospital over the 2 years was 394 (IQR: 161 to
770, range: 1 to 2,076).
We assessed patient characteristics by hospital. The
median patient age was 76 years (IQR by hospital: 64 to 84
years), the median percent of women was 52.7% (IQR:
49.1% to 55.7%), and the median percent of white patients
was 78.4% (IQR: 49.5% to 92.3%). The most common
comorbidities included hypertension (median among hos-
pitals: 70.0%), coronary atherosclerosis (55.1%), cardiac
dysrhythmias (47.9%), disorders of lipid metabolism
(43.5%), renal failure (37.9%), and diabetes without com-
plications (33.7%). Most admissions (median among hos-
pitals: 65.3%, IQR: 52.8% to 75.7%) were through the
emergency department. Medicare was the most common
form of health insurance, accounting for approximately two
thirds (median among hospitals: 65.7%) of patients. The
most frequent procedures performed were renal dialysis and
mechanical ventilation, with median use among hospitals of
5.3% (IQR: 2.4% to 7.6%) and 5.4% (IQR: 3.6% to 7.4%),
respectively. Cardiac procedures were rare, with median use
among hospitals of 1.2% (IQR: 0.0% to 4.4%) for automatic
implantable cardioverter defibrillators with or without car-
diac resynchronization therapy and 0.2% (IQR: 0.0% to
0.8%) for pulmonary artery catheterization.
Hospital use of positive inotropic agents. Of all hospi-
talizations, 13,676 (7.2%) included a treatment with a
positive inotropic agent. Among hospitals, the unadjusted
treatment rate ranged from a minimum of 0% to a maxi-
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October 9, 2012:1402–9 Inotrope Use in Heart Failure Patientsmum of 38.0%. The hospital risk-standardized treatment
rate ranged from a minimum of 0.9% to a maximum of
44.6% (IQR: 4.3% to 9.2%, median: 6.3%) (Fig. 1A).
Dobutamine was most common (range: 0.4% to 47.4%,
IQR: 2.2% to 6.8%, median: 3.7%), followed by dopamine
(range: 0.6% to 16.3%, IQR: 2.5% to 4.7%, median: 3.3%).
Milrinone use was much less on average and highly variable
(range: 0.02% to 67.5%, IQR: 0.5% to 2.0%, median:
0.78%) Fig. 1B).
The pattern of agents used varied widely across hospitals.
Of the 225 hospitals with at least 15 hospitalizations
involving inotrope treatment, 65 (29%) were dobutamine
predominant, 56 (25%) were dopamine predominant, 3
(1%) were milrinone predominant, 71 (32%) were dobut-
amine and dopamine mixed pattern, and 30 (13%) were
dobutamine, dopamine, and milrinone mixed (Table 1).
After adjustment for patient case mix, the likelihood of
treatment with a positive inotropic agent varied by hospital
use patterns (p  0.0001 for the association of use pattern
with percent use). There was also a significant association
between hospital pattern of inotrope use and hospital size
(p  0.02). We did not find a significant relationship
between pattern of inotrope use and teaching status, heart
failure volume, median length of stay, or hospital percent of
Figure 1 Risk-Standardized Rates
of Inotrope Use Across Hospitals
(A) Graph showing the proportion of patients who received any positive inotro-
pic agent at each hospital ranked from lowest to highest use. (B) Graph show-
ing the distribution of hospital risk-standardized rates for each inotropic agent
as well as for any inotrope.H
o T D D M D D p
*P
a
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Inotrope Use in Heart Failure Patients October 9, 2012:1402–9heart transplant or implantation of ventricular assist devices.
Figure 2 illustrates various hospital patterns based on overall
percentage of inotrope use as well as mix of agents used.
There were 151 hospitals with fewer than 15 cases of
inotrope use over 2 years that were not included in the
pattern classifications. Their risk standardized median per-
cent of inotrope use was 4.7% (IQR: 3.8% to 6.2%). These
hospitals were small (median number of beds: 121, IQR: 71
to 216), had a low volume of patients with heart failure
(median: 155, IQR: 87 to 275), and were mainly nonteach-
ing (85.4%).
Patient and hospital characteristics associated with the
use of positive inotropic agents. We assessed the associ-
ation between patient characteristics and inotrope use,
including overall use and use of individual inotropic agent
(Online Appendix). Patients with cardiac arrest and ven-
tricular fibrillation had the highest likelihood of receiving
inotropes, both for combined inotrope use and for use of
each individual agent. The likelihood of receiving inotropes
also was higher in younger patients, most notably for
milrinone. Other comorbidities associated with higher like-
lihood of receiving inotropic treatment included acute
myocardial infarction, valvular disease, fluid and electrolyte
disorders, coagulopathy, cardiac dysrhythmias, coronary
atherosclerosis and other heart disease, renal failure, and
aortic and peripheral arterial embolism or thrombosis.
Female patients had a lower likelihood of being treated with
positive inotropic agents. The ROC curves of these logistic
regression models ranged from 0.69 for dobutamine to 0.75
Figure 2 Hospital Patterns Based on Overall Percentage of Ino
and Mix of Agents Used and Association With Hospita
Among the selected cohort, x, y, and z values were defined as raw percentages of
values through the Scatterplot3d library. We scaled size and color values relative
cle sizes to percentage of overall inotrope use and setting hue saturation value co
between overall inotrope use and mix of agents used and the lack of associationfor dopamine and milrinone.After adjusting for patient characteristics, we assessed the
association between inotrope use and hospital characteristics
by adding the following hospital characteristics to the
model: size, heart failure volume, urban versus rural setting,
teaching versus nonteaching status, and geographic location
by census division (Table 2). These logistic regression
models showed the likelihood of receiving dopamine (OR:
1.13, 95% CI: 1.07 to 1.21) or milrinone (OR: 1.23, 95%
CI: 1.10 to 1.36) to be higher in teaching hospitals and the
odds of receiving dobutamine (OR: 1.31, 95% CI: 1.20 to
1.44) or milrinone (OR: 1.65, 95% CI: 1.33 to 2.05) to be
higher in urban hospitals. Hospitals with the highest odds of
using milrinone had a lower volume of patients with heart
failure (between 26 and 200 hospitalizations over 2 years). The
odds of using positive inotropic agents were highest in the east
south central region (OR: 1.52, 95% CI: 1.41 to 1.65) and
lowest in New England (OR: 0.43, 95% CI: 0.37 to 0.50). The
odds of being treated with any positive inotropic agent were
highest in hospitals having between 251 and 400 beds.
The addition of hospital characteristics to the logistic
regression models was associated with improvement in the
performance of all 5 models (Table 3). The ROC curves
ranged from 0.71 for dobutamine to 0.76 for dopamine and
0.77 for milrinone. However, the best performance was
obtained with the HGLM models that adjusted for patient
case mix and an individual hospital effect as random effects.
The ROC curves for HGLM ranged from 0.77 to 0.88.
Furthermore, the intraclass correlation coefficients of the
HGLM indicated that a noteworthy proportion of the
Use in 187 Hospitals
k-Standardized Mortality Rates
tal-level use of dopamine, dobutamine, and milrinone, respectively. We plotted
r minimum and maximum to fit visual limits of the graphical display. Mapping cir-
risk-standardized mortality rates (RSMR) illustrates the positive association
spital RSMR.trope
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October 9, 2012:1402–9 Inotrope Use in Heart Failure Patientsinstitutional effect after accounting for differences in patient
case mix. Individual institutional effect could explain 34% of
variability in milrinone use, 19% of variability in dobut-
amine use, and 10% of variability in dopamine use.
Use of positive inotropic agents and overall hospital
mortality. When all patients were included, the median of
he unadjusted in-hospital mortality rates was 4.4% (IQR:
.2% to 5.7%). The median of the in-hospital RSMR was
.7% (IQR: 3.9% to 5.5%). There was no significant relation-
hip between RSMR and hospital percent of inotrope use or
ospital pattern of use (Table 1 and 4) (Fig. 2). When we
tratified hospitals by the crude percent of inotrope use
eighted for heart failure volume, we found no difference in
SMR between hospitals in the top and bottom tenth per-
entiles. When we stratified hospitals by use of heart transplant
r ventricular assist device, we found no association between
SMR and percent of inotrope use.
Hospital Factors Associated With the Use of Positive Inotropic AgeTable 2 Hospital Factors Associated With the Use of Positive I
Characteristic Inotrope Do
Annual heart failure volume
25 1.90 (0.92–3.92) 1.49
26–200 0.96 (0.85–1.08) 0.90
201–500 0.87 (0.80–0.93) 0.76
501–1,000 1.00 (0.95–1.05) 1.00
1,001–1,500 1.00 (ref) 1.00
1,500 0.94 (0.90–0.99) 0.94
Hospital size (no. of beds)
1–100 1.00 (ref) 1.00
101–250 1.34 (1.18–1.52) 1.29
251–400 1.69 (1.49–1.92) 1.63
400 1.55 (1.36–1.77) 1.51
Urban (vs. rural) 1.20 (1.12–1.28) 1.31
Teaching (vs. nonteaching) 0.99 (0.94–1.03) 0.87
Location by census division
East south central 1.52 (1.41–1.65) 1.72
Middle Atlantic 0.60 (0.56–0.65) 0.52
Mountain 0.84 (0.75–0.94) 0.75
New England 0.43 (0.37–0.50) 0.28
Pacific 0.75 (0.70–0.81) 0.62
South Atlantic 0.78 (0.73–0.83) 0.61
West north central 0.80 (0.73–0.87) 0.75
West south central 1.00 (0.93–1.08) 0.84
East north central 1.00 (ref) 1.00
Importance of Institutional Factor in Variation oTable 3 Importance of Institutional Factor i
No. of Patients (%)
(N  189,948)
ROC Curve with
Institutional Effe
Any inotrope 13,728 (7.2) 0.706
Dobutamine 7,562 (4.0) 0.686
Dopamine 6,482 (3.4) 0.752
Milrinone 2,025 (1.1) 0.745
*Logistic regression models including patient characteristics as cov
hospital characteristics as covariates. ‡Hierarchical logistic regression mode
ICC  intraclass correlation coefficient; ROC  receiver operating charaiscussion
n this large observational study, we found marked differ-
nces in the patterns of use of positive inotropic agents
mong a diverse group of hospitals in the United States.
ariations in rates and types of medication reflected differ-
nces in hospitals as well as patient characteristics. We did
ot find an association between patterns of use and in-
ospital RSMR or length of stay.
Despite the potential harm associated with positive ino-
ropic agents (16,17) and the lack of strong endorsement by
linical practice guidelines, they are commonly used. Guide-
ines state that inotropes should be confined to carefully
elected patients with low blood pressure and reduced
ardiac output who can have blood pressure and heart
hythm monitored closely (9). Registries suggest that this
roup represents approximately 3% of all patients hospital-
pic Agents
dds Ratio (95% Confidence Interval)
ine Dopamine Milrinone
4.16) 2.09 (0.85–5.14) 0.01 (0.01-9,999.99)
1.06) 0.89 (0.75–1.06) 1.69 (1.25–2.29)
0.84) 1.06 (0.95–1.18) 0.76 (0.60–0.96)
1.07) 1.04 (0.96–1.12) 1.01 (0.88–1.15)
1.00 (ref) 1.00 (ref)
1.00) 0.91 (0.84–0.98) 1.09 (0.97–1.23)
1.00 (ref) 1.00 (ref)
1.53) 1.28 (1.08–1.51) 2.56 (1.46–4.50)
1.93) 1.45 (1.22–1.72) 5.28 (3.02–9.22)
1.80) 1.35 (1.13–1.61) 4.77 (2.72–8.39)
1.44) 1.00 (0.91–1.10) 1.65 (1.33–2.05)
0.93) 1.13 (1.07–1.21) 1.23 (1.10–1.36)
1.89) 1.32 (1.16–1.49) 1.08 (0.87–1.33)
0.56) 0.72 (0.65–0.80) 1.06 (0.91–1.24)
0.87) 1.16 (0.99–1.36) 1.43 (1.11–1.85)
0.35) 0.75 (0.62–0.92) 0.42 (0.28–0.63)
0.68) 1.33 (1.20–1.48) 0.43 (0.34–0.54)
0.66) 1.19 (1.09–1.30) 0.90 (0.77–1.04)
0.84) 1.05 (0.92–1.19) 0.56 (0.42–0.73)
0.93) 1.41 (1.27–1.58) 1.07 (0.90–1.29)
1.00 (ref) 1.00 (ref)
rope Useiation of Inotrope Use
ROC Curve with General
Institutional
Characteristics†
ROC Curve with
Institutional
Effect‡ ICC
0.721 0.769 0.113
0.714 0.789 0.189
0.760 0.802 0.095
0.774 0.877 0.340
. †Logistic regression models including patient characteristics andntsnotro
O
butam
(0.53–
(0.77–
(0.69–
(0.94–
(ref)
(0.88–
(ref)
(1.09–
(1.37–
(1.27–
(1.20–
(0.83–
(1.57–
(0.47–
(0.65–
(0.23–
(0.56–
(0.56–
(0.67–
(0.77–f Inotn Var
out
ct*
ariates
ls including patient characteristics and hospital random effects.
cteristic.
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that many more (7% to 12%) patients are being treated with
these agents (19,20). In the Acute Decompensated Heart
Failure National Registry, the mean systolic blood pressure
for patients treated with dobutamine was 124.0  29.3 mm Hg
and 121.3  27.4 mm Hg for those treated with milrinone.
Of the 6,198 patients (9% of the total cohort) who were
treated with these agents, only 507 (8%) had a systolic
blood pressure of 90 mm Hg (19). The Evaluation
Study of Congestive Heart Failure and Pulmonary Artery
Catheterization Effectiveness reported that the use of
vasoactive therapy among its participants was not signif-
icantly influenced by blood pressure or cardiac index (21).
The pattern of agents used also was quite variable
between hospitals. Overall rates of use were related to the
mix of agents, with the highest percentage of overall
inotropic use found in milrinone-predominant hospitals. In
the absence of evidence about the comparative effectiveness
of these drugs in patients with heart failure, the likelihood of
a patient being treated with a specific agent seems depen-
dent mostly on the institution to which the patient is
admitted. Despite concerns about the safety of inotrope use,
we failed to find differences in mortality or length of stay.
Nevertheless, given that hospitalizations for heart failure are
common and that inotropic agents have potential for harm
in at least some patient populations, the observed variation
in patterns of practice highlights the urgent need for greater
evidence to guide these care decisions.
Study limitations. There are several limitations to con-
sider. First, hospitals in the Premier network may not be a
representative sample of all hospitals in the United States.
Association Between Hospital Use of Inotropesand In-Hospital Risk-Standardized Mortality RateTable 4 Association Be we n H spital Use of Inotropesand In-Hospital Risk-Standardized Mortality Rate
% Median (IQR)
p ValueInotrope Use RSMR
All hospitals (n  283) 6.1 (3.9–9.0) 4.7 (3.9–5.5) 0.358
All hospitals stratified by use
of inotropic agents*
(n  283)
Top 10th percentile 14.9 (13.9–17.6) 4.6 (3.9–5.6) 0.445
11th–24th percentile 10.4 (9.7–11.1) 4.6 (3.9–5.5)
25th–75th percentile 6.1 (5.0–7.5) 4.7 (4.0–5.5)
76th–89th percentile 3.3 (2.8–3.6) 4.3 (3.6–5.7)
Bottom 10th percentile 1.8 (1.4–2.1) 4.7 (4.1–5.9)
VAD/heart transplant
hospitals (n  25)
8.7 (6.8–11.7) 4.5 (3.9–5.3) 0.916
Non-VAD/heart transplant
hospitals (n  258)
Top 10th percentile 14.5 (13.8–17.5) 4.6 (4.1–5.4) 0.484
11th–24th percentile 10.1 (9.5–10.5) 4.8 (3.9–5.8)
25th–75th percentile 5.7 (4.8–7.0) 4.8 (4.0–5.4)
76th–89th percentile 3.2 (2.8–3.5) 4.0 (3.6–5.7)
Bottom 10th percentile 1.8 (1.5–2.1) 4.8 (4.1–6.0)
*Unadjusted rates of inotropic agent use and only hospitals with at least 200 heart failure cases
over the 2 years.
IQR  interquartile range; VAD  ventricular assist device; other abbreviation as in Table 1.However, preliminary comparisons between patient andhospital characteristics for the hospitals that submit data to
Premier and those of the probability sample of hospitals and
patients selected for the National Hospital Discharge Sur-
vey suggest that the patient populations are similar with
regard to age, gender, length of stay, mortality, primary
discharge diagnosis, and primary procedure groups. In
addition, the patients included in our study had very similar
characteristics to those of the heart failure patients described
in registries such as the ADHERE (Acute Decompensated
Heart Failure National Registry) or Get With the
Guidelines-Heart Failure (18,21). Second, this database
does not include clinical data such as left ventricular ejection
fraction, vital signs (e.g., heart rate and blood pressure), or
laboratory test results (serum creatinine) that are important
determinants of inotrope use and may contribute to improv-
ing the risk adjustment for patient case mix across hospitals.
However, the differences we observed are larger than would
be expected based on differences in case mix. Despite the
lack of these clinical and biological data, the performance of
the models (predictive ability) showed that inotrope use at
the hospital level can be modeled adequately when account-
ing for both patient case mix and institutional clustering
effects. Third, we included only the first admission, rather
than all hospitalizations, per patient. This was because
analyses showed that percentage of inotrope use was higher
in patients with multiple hospitalizations. Therefore, in-
cluding all hospitalizations would have overestimated the
relative importance of institution-related factors (versus
patient-related factors) in explaining the variation in ino-
trope use. Indeed, when all hospitalizations per patient were
included, the ICC were slightly higher (0.131 for any
inotrope use, 0.216 for dobutamine, 0.102 for dopamine,
and 0.372 for milrinone).
Our analyses demonstrate that a noteworthy proportion
of the variation observed in inotrope use was related to an
individual institutional effect. This finding is in agreement
with the Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Effectiveness, in which
the most important predictor of use was the study site
(hospital) to which the patient was admitted, despite the
inclusion of more patient-level clinical and biological data in
the multivariate analysis (21).
Conclusions
The marked differences that we observed in the rates and
patterns of inotrope use in the treatment of patients hospi-
talized with heart failure in the United States are attributed
in part to unmeasured institutional factors, making the
likelihood and type of treatment with an inotropic agent for
any given patient highly dependent on the hospital to which
the patient is admitted. This study heralds an urgent need
for further investigation to define the proper role of inotro-
pic agents in the treatment of patients with decompensated
heart failure.
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